ArticlePsychedelic medicine (New Rochelle, N.Y.)2023
Preventing the Gaps in Psychedelic Research from Becoming Practice Pitfalls: A Translational Research Agenda.
Article in Psychedelic medicine (New Rochelle, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Not a Standalone Treatment: Considerations for Psychedelic-Assisted Therapy.Brain and behavior · 2026Review
- "I've learned that I'm open-minded to this possibility": A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke.Addiction science & clinical practice · 2025Article
- Advancing Psychedelic-Assisted Therapy in Missouri (MO-PAT): Innovation at the Speed of Safety.Missouri medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The reemergence of psychedelic medicines as clinical treatments has generated considerable interest in both professional and popular arenas. Although evidence is promising for psychedelic-assisted therapy (PAT), there is much that is not yet known and needs to be researched so as to understand how to safely and effectively utilize PAT in clinical populations and to most effectively deploy PAT to patients. In addition, non-clinical stakeholders introduce interests and agendas that may differ from those of clinicians. This article reviews the history of how psychedelics were initially outlawed and then introduces research questions that will help to fill these gaps in knowledge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.